<DOC>
	<DOCNO>NCT02955212</DOCNO>
	<brief_summary>This Phase 3 multicenter study include two period . Period 1 12-week , randomize , double-blind , parallel-group , placebo-controlled period design compare safety efficacy ABT-494 versus placebo treatment sign symptoms participant moderately severely active RA stable dose csDMARDs inadequate response csDMARDs . Period 2 blind 52 week extension period evaluate long-term safety , tolerability , efficacy ABT-494 participant RA complete Period 1 .</brief_summary>
	<brief_title>A Study With ABT-494 Subjects From China Selected Countries With Moderately Severely Active Rheumatoid Arthritis Who Have Had Inadequate Response Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs ( csDMARDs )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Diagnosis Rheumatoid Arthritis ( RA ) &gt; = 3 month also fulfill 2010 American College Rheumatology ( ACR ) / European League Against Rheumatism ( EULAR ) classification criterion RA . Participants receive csDMARD therapy &gt; = 3 month stable dose &gt; = 4 week prior first dose study drug . 1 . Participants must fail ( lack efficacy ) least one following : methotrexate ( MTX ) , sulfasalazine , leflunomide . 2 . The following csDMARDs allow : oral parenteral MTX , sulfasalazine , hydroxychloroquine , chloroquine , leflunomide . 3 . A combination two background csDMARDs allow except combination MTX leflunomide . Participant meet follow disease activity criterion : 1 . &gt; = 6 swollen joint ( base 66 joint count ) â‰¥ 6 tender joint ( base 68 joint count ) Screening Baseline Visits ; Prior exposure Janus kinase ( JAK ) inhibitor ( include limit tofacitinib , baricitinib , filgotinib ) . Participants prior exposure Biological diseasemodifying antirheumatic drug ( bDMARD ) therapy . History arthritis onset prior age 17 year current diagnosis inflammatory joint disease RA ( include limit gout , systemic lupus erythematosus , psoriatic arthritis , axial spondyloarthritis include ankylose spondylitis nonradiographic axial spondyloarthritis , reactive arthritis , overlap connective tissue disease , scleroderma , polymyositis , dermatomyositis , fibromyalgia [ currently active symptom ] . Current diagnosis secondary Sjogren 's Syndrome permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs ( csDMARDs )</keyword>
	<keyword>ABT-494</keyword>
</DOC>